Back to today’s briefing

Story perspectives

Analysts Boost Atossa Therapeutics Targets Amid Promising Oncology Results

3/29/2025

49 8

Summary

Story summary

Maxim Group's Jason McCarthy has reaffirmed a Buy rating for Atossa Therapeutics (ATOS), setting a $4.00 price target, fueled by promising developments in oncology, especially with endoxifen for metastatic breast cancer. Encouraging early clinical results and a robust cash reserve bolster this optimistic view. H.C. Wainwright echoes this sentiment with a $7.00 target.

1 of 1

Story summary

Maxim Group's Jason McCarthy has reaffirmed a Buy rating for Atossa Therapeutics (ATOS), setting a $4.00 price target, fueled by promising developments in oncology, especially with endoxifen for metastatic breast cancer. Encouraging early clinical results and a robust cash reserve bolster this optimistic view. H.C. Wainwright echoes this sentiment with a $7.00 target.